EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pancreatic Cancer: Pathogenesis and Clinical Studies

Kexun Zhou, Yingping Liu, Chuanyun Tang, Hong Zhu

MedComm · 2025-04 · 6 (4)

DOI: 10.1002/mco2.70162 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 02.04.2025. Verfasst von Kexun Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 381 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) is a highly lethal malignancy, with pancreatic ductal adenocarcinoma (PDAC) being the most common and aggressive subtype, characterized by late diagnosis, aggressive progression, and resistance to conventional therapies. Despite advances in understanding its pathogenesis, including the identification of common genetic mutations (e.g., KRAS, TP53, CDKN2A, SMAD4) and dysregulated signaling pathways (e.g., KRAS–MAPK, PI3K–AKT, and TGF‐β pathways), effective therapeutic strategies remain limited. Current treatment modalities including chemotherapy, targeted therapy, immunotherapy, radiotherapy, and emerging therapies such as antibody–drug conjugates (ADCs), chimeric antigen receptor T (CAR‐T) cells, oncolytic viruses (OVs), cancer vaccines, and bispecific antibodies (BsAbs), face significant challenges. This review comprehensively summarizes these treatment approaches, emphasizing their mechanisms, limitations, and potential solutions, to overcome these bottlenecks. By integrating recent advancements and outlining critical challenges, this review aims to provide insights into future directions and guide the development of more effective treatment strategies for PC, with a specific focus on PDAC. Our work underscores the urgency of addressing the unmet needs in PDAC therapy and highlights promising areas for innovation in this field.

Schlagwörter

Stichwörter der Autor:innen

gene alterationpancreatic ductal adenocarcinomapersonalized managementsignaling pathwaystreatment development

Autor:innen und Institutionen

  • Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu China.
  • Department of Radiotherapy Cancer Hospital Chinese Academy of Medical Sciences Beijing China.
  • The First Clinical Medical College of Nanchang University Nanchang University Nanchang China.
  • Division of Abdominal Tumor Multimodality Treatment Cancer Center West China Hospital Sichuan University Chengdu China.

Zitieren

APA

Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025). Pancreatic Cancer: Pathogenesis and Clinical Studies. MedComm, 6(4). https://doi.org/10.1002/mco2.70162

Vancouver

Zhou K, Liu Y, Tang C, Zhu H. Pancreatic Cancer: Pathogenesis and Clinical Studies. MedComm. 2025;6(4). doi:10.1002/mco2.70162

BibTeX
@article{Zhou2025,
  author = {Zhou, Kexun and Liu, Yingping and Tang, Chuanyun and Zhu, Hong},
  title = {Pancreatic Cancer: Pathogenesis and Clinical Studies},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {4},
  doi = {10.1002/mco2.70162}
}
Kostenlos starten →